↓ Skip to main content

Use of subsequent PET/CT in diffuse large B‐cell lymphoma patients in complete remission following primary therapy

Overview of attention for article published in Cancer Communications, November 2014
Altmetric Badge

Mentioned by

policy
1 policy source
twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Use of subsequent PET/CT in diffuse large B‐cell lymphoma patients in complete remission following primary therapy
Published in
Cancer Communications, November 2014
DOI 10.5732/cjc.014.10124
Pubmed ID
Authors

Xu Zhang, Wei Fan, Zhong‐Jun Xia, Ying‐Ying Hu, Xiao‐Ping Lin, Ya‐Rui Zhang, Zhi‐Ming Li, Pei‐Yan Liang, Yuan‐Hua Li

Abstract

Interim 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (I-PET/CT) is a powerful tool for monitoring the response to therapy in diffuse large B-cell lymphoma (DLBCL). This retrospective study aimed to determine when and how to use I-PET/CT in DLBCL. A total of 197 patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were enrolled between October 2005 and July 2011; PET/CT was performed at the time of diagnosis (PET/CT0), after 2 and 4 cycles of chemotherapy (PET/CT2 and PET/CT4, respectively), and at the end of treatment (F-PET/CT). According to the International Harmonization Project for Response Criteria in Lymphoma, 110 patients had negative PET/CT2 scans, and 87 had positive PET/CT2 scans. The PET/CT2-negative patients had significantly higher 3-year progression-free survival rate (75.8% vs. 38.2%) and 3-year overall survival rate (93.5% vs. 55.6%) than PET/CT2-positive patients. All PET/CT2-negative patients remained negative at PET/CT4, but 3 were positive at F-PET/CT. Among the 87 PET/CT2-positive patients, 57 remained positive at F-PET/CT, and 32 progressed during chemotherapy (15 at PET/CT4 and 17 at F-PET/CT). Comparing PET/CT4 with PET/CT0, 7 patients exhibited progression, and 8 achieved partial remission. Comparing F-PET/CT with PET/CT0, 10 patients exhibited progression, and 7 achieved partial remission. In conclusion, our results indicate that I-PET/CT should be performed after 2 rather than 4 cycles of immunochemotherapy in DLBCL patients. There is a limited role for subsequent PET/CT in the detection of relapse in PET/CT2-negative patients, but repeat PET/CT is required if the PET/CT2 findings are positive.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 15%
Unknown 11 85%

Demographic breakdown

Readers by professional status Count As %
Other 3 23%
Student > Bachelor 2 15%
Student > Ph. D. Student 2 15%
Researcher 2 15%
Student > Master 2 15%
Other 1 8%
Unknown 1 8%
Readers by discipline Count As %
Medicine and Dentistry 8 62%
Computer Science 1 8%
Nursing and Health Professions 1 8%
Unknown 3 23%